Document Detail


Oral tegafur in the treatment of metastatic breast cancer: a phase II study.
MedLine Citation:
PMID:  8484979     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Between February 1985 and October 1989, 26 patients previously treated for metastatic breast cancer received oral tegafur, at a median daily dose of 1200 mg. Of these, 21 were evaluable for response. The overall response rate was 29%; six (two in lungs, two in skin and two in lymph nodes) of 44 evaluable lesions (14%) responded to therapy. Haematological toxicity was mild, and no other dose-limiting toxicity was seen. The data indicate some activity in heavily pretreated metastatic breast cancer even after previous 5-FU therapy.
Authors:
M J Kajanti; S O Pyrhönen; A G Maiche
Related Documents :
2655099 - Overview of carboplatin: replacing, complementing, and extending the therapeutic horizo...
11313169 - Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
19139109 - Ixabepilone: targeting betaiii-tubulin expression in taxane-resistant malignancies.
10482199 - Combination therapy with trastuzumab (herceptin) and cisplatin for chemoresistant metas...
20447949 - Single premedication dose of dexamethasone 20 mg iv before docetaxel administration.
6538489 - Phase ii study of 9-hydroxy-2n-methylellipticinium acetate.
20954719 - Lectin-based biosensor strategy for electrochemical assay of glycan expression on livin...
17441399 - Modeling a better way: navigating the healthcare system for patients with lung cancer.
1115529 - Inhalation carcinogenicity of alpha halo ethers. i. the acute inhalation toxicity of ch...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  29A     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1993  
Date Detail:
Created Date:  1993-06-07     Completed Date:  1993-06-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  863-6     Citation Subset:  IM    
Affiliation:
Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Blood Cell Count
Bone Neoplasms / secondary
Breast Neoplasms / blood,  drug therapy*
Female
Humans
Lung Neoplasms / secondary
Lymphatic Metastasis
Middle Aged
Skin Neoplasms / secondary
Tegafur / administration & dosage,  therapeutic use*
Chemical
Reg. No./Substance:
17902-23-7/Tegafur

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Psychological reactions in public melanoma screening.
Next Document:  Prevalence of anticipatory nausea and other side-effects in cancer patients receiving chemotherapy.